Uric acid as a risk factor for cardiovascular diseases

Czech version

Authors: Ľubica Cibičková; David Karásek
Authors‘ workplace: III. interní klinika – nefrologie, revmatologie, endokrinologie LF UP a FN, Olomouc
Published in: Vnitř Lék 2016; 62(11): 919-923
Category: Reviews

Část práce byla přednesena formou přednášky pod názvem „Kyselina močová a její vztah k parametrům metabolického syndromu – staro-nové poznatky“ na Šobrově dni 8. 6. 2016 v Praze.

Overview

According to current knowledge, uric acid plays an important role in pathogenesis of civilizational diseases – obesity, metabolic syndrome and cardiovascular diseases. Uric acid has become an independent risk factor of morbidity and mortality. It is questionable, if the relationship between uric acid and cardiovascular diseases is direct (through influence on endothelial dysfunction, oxidative stress and inflammation) or indirect (mediated by known risk factors of cardiovascular diseases – metabolic syndrome, obesity, insulin resistance and hypertension). This article describes relationship between particular cardiovascular risk factors and uric acid. However, on the basis of current knowledge it is not possible to recommend treatment of hyperuricemia in order to decrease cardiovascular risk.

Key words:
fructose – insulin resistance – metabolic syndrome – uric acid – visceral obesity

Sources

1. Sucharda P. Překvapivě starý kostlivec ve skříni – editorial. Vnitř Lék 2015; 61(1): 10–12.

2. Kanbay M, Jensen T, Solak Y et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med 2016; 29: 3–8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2015.11.026>.

3. Němec P. Dna a kardiovaskulární riziko. Vnitř Lék 2014; 60(10): 893–901.

4. Feig DI, Kang DH, Johnson R. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811–1821. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0800885>. Erratum in N Engl J Med 2010; 362(23): 2235.

5. Johnson RJ, Segal MS, Sautin Y et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007; 86(4): 899–906.

6. Koborova I, Gurecka R, Hlavata A et al. Asymptomatická hyperurikémie a matebolický syndróm u mladistvých. Vnitř Lék 2015; 61(1): 42–49.

7. Nakagawa T, Tuttle KR, Short RA et al. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005; 1(2): 80–86.

8. Stanhope KL, Schwarz JM, Keim NL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119(5): 1322–1334. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI37385>.

9. Linhart A, Rob D. Význam kyseliny močové a terapie alopurinolem v ovlivnění kardiovaskulárních onemocnění. Vnitř Lék 2015; 61(5): 421–430.

10. Carbone F, Montecucco F, Mach F et al. The liver and the kidney: Two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thromb Haemost 2013; 110(5): 940–958. Dostupné z DOI: <http://dx.doi.org/10.1160/TH13–06–0499>.

11. Yuan H, Yu C, Li X et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab 2015; 100(11): 4198–4207. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2015–2527>.

12. DeBosh BJ, Kluth O, Fujiwara H et al. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC219. Nat Commun 2014; 5: 4642. Dostupné z DOI: <http://dx.doi.org/10.1038/ncomms5642>.

13. Cibickova L, Langova K, Vaverkova H et al. Correlation of uric acid levels and parameters of metabolic syndrome. Phys Res 2016; accepted for publication.

14. Sucharda P. Co spojuje obezitu a aterosklerózu? Vnitř Lék 2010; 56(4): 289–291.

15. Lanaspa MA, Sanchez-Lozada LG, Ciecerchi C et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One 2012; 7(10): e47948. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0047948>.

16. Fruehwald-Schultes B, Peters A, Kern W et al. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999; 48(6): 677–680.

17. Sautin YY, Nakagawa T, Zharikov S et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293(2): C584-C596. Erratum in Am J Physiol Cell Physiol 2010; 299(3): C726.

18. Guerra AF Circulating levels of uric acid and risk for metabolic syndrome. Curr Diabetes Rev 2015; [Epub ahead of print]

19. Ciarla S, Giorgini P, Struglia M et al. Associations between low levels of serum uric acid and cardiometabolic parameters. Arch Physiol Biochem 2015; 121(4): 139–143.

20. Takahashi S, Yamamoto T, Tsutsumi Z et al. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism 1997; 46(10): 1162–1165.

21. Masuo K, Kawaguchi H, Mikami H et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42(4): 474–480.

22. Hallfrish J. Metabolic effects of dietary fructose. FASEB J 1990; 4(9): 2652–2660.

23. Bhole V, Choi JWJ, Kim SW et al. Serum uric acid levels ant the risk of type 2 diabetes: a prospective study. Am J Med 2010; 123(10): 957–961. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2010.03.027>.

24. Facchini F, Chen YD, Hollenbeck CB et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266(21): 3008–3011.

25. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183–1190.

26. Perlstein TS, Gumieniak O, Williams GH et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48(6): 1031–1036.

27. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15(6): 435–442. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1751–7176.2012.00701.x>.

28. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25(1): 39–42.

29. Spahic E, Hasic S, Kiseljakovic E et al. Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndromes. Med Glas (Zenica) 2015; 12(2): 128–132. Dostupné z DOI: <http://dx.doi.org/10.17392/821–15>.

30. Sun HL, Pie D, Lue KH et al. Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study. PLoS ONE 2015; 10(11): e0143786. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0143786>.

31. Johnson RJ, Tittre S, Cade JR et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25(1): 3–8.

32. Stack AG, Hanley A, Casserly LF et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013; 106(7): 647–658.